X4 Pharmaceuticals (XFOR) has disclosed a new risk, in the Share Price & Shareholder Rights category.
X4 Pharmaceuticals currently faces the risk of being delisted from Nasdaq due to non-compliance with the minimum bid price requirement. The company’s stock has failed to meet the $1.00 per share threshold over a consecutive 30-day period, prompting a warning from Nasdaq. X4 Pharmaceuticals has until May 13, 2024, to rectify the situation; however, failure to do so could severely impact the company’s stock market price, liquidity, and ability to raise capital, leading to a host of negative consequences including the potential loss of investor confidence and reduced market accessibility.
Overall, Wall Street has a Moderate Buy consensus rating on XFOR stock based on 1 Buy.
To learn more about X4 Pharmaceuticals’ risk factors, click here.
